InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Stock Information for DigiAsia Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About DigiAsia Corp.

InMed Provides Update on BayMedica Commercial Business
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.